However, pCR was achieved with crucial improvement in the prognosis for the patient. In clinical practice, an important open debate is the histological confirmation of complete CR. for surgery; bevacizumab before surgery has been shown to be feasible and safe, although issues still exist concerning possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response like a surrogate for pathological response is definitely even more relevant when antiangiogenic treatments are used. Superb reactions to bevacizumab-containing regimens do occur and referral PD 169316 to medical oncology is definitely a crucial step for paperwork of total pathological response. Background At present, the only available treatment associated with long-term survival in individuals with colorectal malignancy metastases is definitely liver resection with 5-yr survival rates ranging from 21% to 58%[1]. Regrettably, only 10% to 25% of individuals with colorectal liver metastases are eligible for medical resection. The standard of care and attention in unresectable individuals is definitely palliative chemotherapy in order to improve overall survival; however, chemotherapy may also be used in an attempt to PD 169316 render liver metastases PD 169316 amenable to medical resection. Thanks to systemic chemotherapy, resections of in the beginning unresectable liver metastases have been reported in about 13% of individuals [2] with successful 5-yr overall survival comparable to individuals primarily respectable[3]. In resectable individuals, pre-operative chemotherapy may increase the R0 resection rate and facilitate limited hepatectomies, hence sparing normal liver parenchyma and improving post-operative recovery[4]. The objective of this approach is also to control the metastatic disease in order to avoid surgery in individuals with rapidly progressive disease associated with a poor end result after hepatic resection[5]. Gradually, pCR seems to be correlated with longer overall survival periods and is recognized as an important prognostic factor in individuals treated with pre-operative chemotherapy for breast, esophageal, gastric and rectal malignancy primitive tumors [6,7]. Interestingly, the pCR, still reported like a rare situation with an overall incidence of 4% of all resected individuals, is going to achieve medical significance implying the complete absence of residual neoplastic cells on examination by a pathologist [8]. In a recent study by Adam em et al. /em , the pCR of liver metastases was associated with a 5-yr overall survival of 76%[9]. Total metabolic response on PET scan after neoadjuvant chemotherapy is not always a reliable indication of pCR. Even though the PET scan has the advantage of combining practical and anatomic imaging in an integrated scanner, discordant data from your literature indicate the limitations of the PET scan in restaging individuals with hepatic colorectal metastases following neoadjuvant chemotherapy; medical decision-making often requires info from multiple modalities. Lesions not seen on imaging are still found to have viable tumors when resected or to lead to recurrence without resection[10]. pCR is definitely described as becoming more frequent than CR, indicating that total necrosis of tumor cells does not imply disappearance of metastasis in pre-operative imaging and does not necessarily correspond to CR[9]. In recent years, novel biological providers have LSP1 antibody also changed the standard of care for metastatic colorectal malignancy and may possess implications for neoadjuvant treatment The limitation of the radiologic assessment of response like a surrogate for pathological response is definitely even more relevant when antiangiogenic treatments are used. We report a case of pCR after main chemotherapy of four programs of FOLFOX-6 plus bevacizumab (much shorter than expected because of poor tolerability) of colorectal liver metastases confirmed by laparoscopic liver biopsies; CT and PET scans showed good correspondence between the two imaging techniques and between medical and pathological response. After 36 months, the patient is definitely alive and disease free. Case demonstration In June 2006, a healthy 72-year-old woman presented with rectal.
